Safety Study of CAT-8015 to Treat Advanced B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (NHL or CLL)
Status:
Completed
Trial end date:
2013-03-04
Target enrollment:
Participant gender:
Summary
The primary objectives of this study are to determine the maximum tolerated dose (MTD) or
optimal biologic dose (OBD) and safety profile of CAT-8015 in participants with relapsed or
refractory advanced B-cell NHL (diffuse large B-cell lymphoma [DLBCL], follicular lymphoma
[FL], mantle cell lymphoma [MCL]) or CLL.